Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Low dose of telmisartan (Drug); High dose of telmisartan (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to
establish the effect on patient's quality of life scores.
Clinical Details
Official title: An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change in diastolic blood pressureChange in systolic blood pressure Changes from baseline in the quality of life (QOL) scores by patient self-assessment
Secondary outcome: Assessment of blood pressure control rateAssessment of systolic blood pressure response rate Assessment of diastolic blood pressure response rate Change from baseline in pulse pressure Number of patients with adverse events
Eligibility
Minimum age: 20 Years.
Maximum age: 93 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg,
and/or systolic blood pressure 140-159 mmHg)
- Signed informed consent form
Exclusion Criteria:
- Females of childbearing potential
Locations and Contacts
Additional Information
Starting date: September 1999
Last updated: September 16, 2014
|